Miles Capital’s Cytokinetics CYTK Stock Holding History

Miles Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,781	Closed	-$200K	–	191
2017 Q3	$200K	Buy	+13,781	New	+$188K	0.11%	171

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Miles Capital's CYTK Position: Q4 2017 in Review

Miles Capital sold out of Cytokinetics (CYTK) in Q4 2017, closing a stake of 13,781 shares — an estimated $200K sold.

Miles Capital first reported a position in CYTK in Q3 2017 and held it in 1 quarter. The position peaked at $200K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

Miles Capital reported no remaining Cytokinetics position as of Q4 2017 after selling out during the quarter.
Miles Capital sold 13,781 Cytokinetics shares in Q4 2017, an estimated $200K.
Miles Capital first reported a position in Cytokinetics in Q3 2017 and held it in 1 quarter.
Miles Capital's Cytokinetics position peaked at $200K in Q3 2017.
134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Miles Capital's 13F filing for Q4 2017, filed 31 Jan 2018.